GE HealthCare has entered into a definitive agreement to complete the SOFIE Biosciences acquisition for $945 million in cash, marking a major strategic expansion of its radiopharmaceutical footprint across the United States. Under the terms of the transaction, private equity firm Trilantic North America will sell SOFIE Biosciences to GE HealthCare, with the acquired operations slated to join GE HealthCare’s Pharmaceutical Diagnostics business segment. The transaction is projected to close in the first half of 2027, subject to standard regulatory reviews and customary closing conditions. By incorporating SOFIE’s nationwide network—which includes 15 contract manufacturing organization (CMO) sites equipped with 21 cyclotrons—GE HealthCare seeks to address key logistical hurdles in manufacturing and delivering short-lived Positron Emission Tomography (PET) radiopharmaceuticals directly to care sites.
What Changed: The $945 Million Cash Transaction
The agreement between GE HealthCare and Trilantic North America establishes an all-cash valuation of $945 million for SOFIE Biosciences. This transaction represents a definitive shift in ownership for SOFIE, bringing its specialized infrastructure, development programs, and production facilities under GE HealthCare’s corporate umbrella.
Upon transaction completion, SOFIE Biosciences will be integrated into GE HealthCare’s Pharmaceutical Diagnostics segment. This segment specializes in developing and commercializing diagnostic agents used in medical imaging modalities, including nuclear medicine, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound. By adding SOFIE’s extensive physical footprint to this business unit, GE HealthCare intends to enhance its operational baseline in high-demand molecular imaging markets across the United States.
The deal timeline targets a formal closing within the first half of 2027. Final execution remains dependent upon achieving standard regulatory approvals and fulfilling customary closing conditions required for transactions of this scale in the healthcare and life sciences sectors.
Operational Footprint: 15 CMO Sites and 21 Cyclotrons
A central component of the acquisition is SOFIE’s operational infrastructure distributed throughout the United States. SOFIE operates a network of 15 contract manufacturing organization (CMO) facilities that provide regional radiopharmaceutical manufacturing capabilities. These specialized sites enable the synthesis, quality control, packaging, and rapid dispatch of diagnostic radiotracers.
Core to this operational network are 21 cyclotrons spread across SOFIE’s facilities. Cyclotrons are particle accelerators used to bombard target elements with charged particles, producing short-lived radioisotopes required for PET imaging procedures. Maintaining a distributed network of 21 cyclotrons allows manufacturing operations to occur close to major population centers and clinical facilities.
In addition to its standard CMO facilities, SOFIE operates a dedicated contract development and manufacturing organization (CDMO) site explicitly focused on theranostics. This specialized unit supports the development and production of targeted radiopharmaceutical agents designed to pair diagnostic imaging with targeted therapeutic interventions.
The Technical Challenge of Short Half-Life Radiopharmaceuticals
The operational rationale for acquiring localized manufacturing infrastructure is heavily driven by the physical properties of radiopharmaceutical agents. In PET imaging, fluorine-18 (F18) is one of the most widely utilized radioisotopes due to its optimal decay characteristics for high-resolution diagnostic scans. However, F18 PET drugs possess a strict half-life of 110 minutes.
Because half of the radioactive isotope decays every 110 minutes, the useful lifespan of an F18-labeled drug is measured in hours from the moment synthesis is completed inside a cyclotron facility. Centralized, single-site manufacturing models are economically and logistically unfeasible for short-lived PET tracers, as transportation delays lead to total decay of the active diagnostic product before it can reach a patient.
Consequently, the final step in delivering PET radiopharmaceuticals—moving the finished drug from local cyclotron sites to clinical scan rooms—is inherently time-sensitive. Expanding access to localized manufacturing infrastructure allows producers to shorten delivery distances, minimize transit times, and preserve the radioactive potency necessary for accurate clinical imaging.
Pipeline Analysis: FAPI-74 and Next-Generation Tracers
Beyond physical manufacturing assets, the acquisition impacts key intellectual property and product pipeline assets. SOFIE’s research and development portfolio includes FAPI-74, a Phase III radiopharmaceutical candidate labeled with F18. FAPI-74 is designed to target Fibroblast Activation Protein (FAP), an enzyme overexpressed in the stroma of various solid tumors and stromal tissue in non-cancerous conditions.
Prior to this acquisition agreement, GE HealthCare already secured commercial and development rights for FAPI-74 in regions outside the United States. Completing the acquisition of SOFIE Biosciences will consolidate global oversight for FAPI-74 under GE HealthCare upon closing, aligning domestic distribution and development with its existing international rights.
According to research analyses, FAPI-based radiopharmaceuticals hold significant potential to expand the overall scope of PET imaging. While conventional PET imaging relies heavily on glucose metabolism agents, FAPI agents target stromal activity. This mechanism offers potential clinical applications across both oncology and various non-cancer diseases, including fibrotic and inflammatory conditions.
Commercial Model and Customer Continuity
Following the closing of the transaction, SOFIE Biosciences is slated to continue operating as an independent manufacturing partner to its external customer base. The company will maintain supply agreements and contract manufacturing operations for its existing product portfolio, serving third-party pharmaceutical developers alongside internal corporate priorities.
By retaining an independent CDMO and CMO operating framework, SOFIE can fulfill its commitments to third-party clients that rely on its 15 manufacturing facilities and 21 cyclotrons. This arrangement allows GE HealthCare to capture commercial manufacturing revenues across the broader radiopharmaceutical industry while maintaining reliable supply channels for existing products.
End-to-End Theranostics Integration
The integration of SOFIE into GE HealthCare is designed to strengthen capabilities across multiple stages of the theranostics process. Theranostics represents an integrated healthcare model that combines targeted diagnostic imaging—such as PET scans—with targeted radiotherapeutic agents to identify, treat, and monitor disease processes within individual patients.
Executing an end-to-end theranostics framework requires coordinated infrastructure spanning several distinct technological categories:
- Particle Acceleration: Upstream radioisotope production using cyclotron networks.
- Imaging Hardware: Advanced PET and PET/CT scanner systems for anatomical and functional visualization.
- Digital Workflow Tools: Specialized software platforms for dose management, scheduling, and diagnostic image processing.
- Therapeutic Infrastructure: CDMO and CMO production environments capable of formulating and releasing radiotherapeutics under strict regulatory guidelines.
According to claims regarding the acquisition, adding SOFIE’s manufacturing sites and theranostics-focused CDMO capabilities enables GE HealthCare to provide solutions across a wider portion of this multi-step theranostics continuum. Connecting hardware, digital management systems, and radiopharmaceutical manufacturing is expected to support more reliable patient access to emerging nuclear medicine products as clinical adoption increases.
Regulatory Pathway and Transaction Timeline
The acquisition of SOFIE Biosciences from Trilantic North America remains subject to regulatory review processes and standard closing protocol. Key elements governing the execution timeline include:
- Valuation: $945 million in total cash consideration.
- Target Closing Window: First half of 2027.
- Regulatory Reviews: Customary antitrust and healthcare regulatory approvals in the United States.
- Corporate Entities: Transaction agreements involve GE HealthCare, SOFIE Biosciences, seller Trilantic North America, and associated corporate leadership including Amy Acton.
Until the regulatory reviews complete and customary closing conditions are satisfied in the first half of 2027, SOFIE Biosciences and GE HealthCare will continue to operate as separate independent corporate entities.
Sector Impact and Supply Chain Considerations
The radiopharmaceutical sector requires rigorous coordination due to the physical instability of short-lived isotopes. The 110-minute half-life of F18 drugs imposes strict geographical limits on distribution radiuses surrounding each cyclotron facility. A single disruption at a manufacturing site can interrupt regional patient access to critical diagnostic scans.
By expanding its presence in the time-sensitive final step of delivering PET radiopharmaceuticals to care facilities, GE HealthCare aims to bolster supply chain resilience. Expanding regional cyclotron capacity across 15 CMO locations increases operational redundancies, helping absorb localized technical delays and supporting predictable delivery schedules for healthcare providers.
Furthermore, as Phase III clinical assets like FAPI-74 advance toward commercialization, having established domestic manufacturing infrastructure is critical for scaling clinical supply. The acquisition positions GE HealthCare to manage both drug development and large-scale, distributed production within a single unified organizational segment once the transaction closes in 2027.